Tacrolimus inhibits insulin release and promotes apoptosis of Min6 cells through the inhibition of the PI3K/Akt/mTOR pathway

Tong,Ling; Li,Weiliang; Zhang,Ying; Zhou,Fan; Zhao,Yan; Zhao,Linlin; Liu,Jing; Song,Zhirui; Yu,Mengchen; Zhou,Chengrui; Yu,Airong

doi:10.3892/mmr.2021.12297

Tacrolimus inhibits insulin release and promotes apoptosis of Min6 cells through the inhibition of the PI3K/Akt/mTOR pathway

Authors:
- Ling Tong
- Weiliang Li
- Ying Zhang
- Fan Zhou
- Yan Zhao
- Linlin Zhao
- Jing Liu
- Zhirui Song
- Mengchen Yu
- Chengrui Zhou
- Airong Yu
View Affiliations

Affiliations: Department of Clinical Pharmacy, General Hospital of Central Theater Command, Wuhan, Hubei 430000, P.R. China
Published online on: July 15, 2021 https://doi.org/10.3892/mmr.2021.12297
Article Number: 658

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

As a calcineurin inhibitor, tacrolimus is commonly used as a first‑line immunosuppressant in organ transplant recipients. Post‑transplantation diabetes mellitus (PTDM) is a common complication following kidney transplantation and is associated with immunosuppressant drugs, such as tacrolimus. PTDM caused by tacrolimus may be related to its influence on insulin secretion and insulin resistance. However, the specific mechanism has not been fully elucidated. The aim of the present study was to investigate whether the PI3K/Akt/mTOR signaling pathway served an important role in the pathogenesis of PTDM induced by tacrolimus. In the present study, the Cell Counting Kit‑8 assay was used to measure the effect of tacrolimus on the viability of Min6 mouse insulinoma cells. The effects of tacrolimus on the insulin secretion and the activity of caspase‑3 of Min6 cells stimulated by glucose exposure were measured by ELISA. Superoxide dismutase (SOD) and malondialdehyde (MDA) levels were measured using WST‑8 and thiobarbituric acid assays, respectively. The effects of tacrolimus on the mRNA expression levels of PI3K, Akt and mTOR were detected by reverse transcription‑quantitative PCR (RT‑qPCR), whereas the protein expression levels of PI3K, Akt, mTOR, phosphorylated (p)‑AKT and p‑mTOR in Min6 cells were assessed using western blotting. The present data indicated that, compared with the control group, 5, 25 and 50 ng/ml tacrolimus treatment could inhibit the insulin secretion of Min6 cells stimulated by glucose solution, and 50 ng/ml tacrolimus could notably decrease the stimulation index (P<0.05). Moreover, 50 ng/ml tacrolimus markedly increased the activity of caspase‑3 by 175.1% (P<0.05), it also decreased the SOD activity (P<0.01) and increased MDA levels (P<0.05). The RT‑qPCR results demonstrated that the mRNA expression levels of PI3K, Akt and mTOR were downregulated by 25 and 50 ng/ml tacrolimus (P<0.01). Furthermore, the western blotting results suggested that tacrolimus had no significant effects on the expression levels of total PI3K, Akt and mTOR proteins (P>0.05), but 25 and 50 ng/ml tacrolimus could significantly inhibit the expression levels of p‑Akt and p‑mTOR (P<0.01). In conclusion, tacrolimus decreased the activity and insulin secretion of pancreatic β cells and induced the apoptosis of islet β cells by inhibiting the mRNA expression levels of PI3K, Akt and mTOR and reducing the phosphorylation of Akt and mTOR proteins in the PI3K/Akt/mTOR signaling pathway, which may ultimately lead to the occurrence of diabetes mellitus, and may be considered as one of the specific mechanisms of PTDM caused by tacrolimus.

View Figures

View References

1	Gomes MB and Cobas RA: Post-transplant diabetes mellitus. Diabetol Metab Syndr. 1:142009. View Article : Google Scholar : PubMed/NCBI
2	Jenssen T and Hartmann A: Emerging treatments for post-transplantation diabetes mellitus. Nat Rev Nephrol. 11:465–477. 2015. View Article : Google Scholar : PubMed/NCBI
3	Cosio FG, Kudva Y, van der Velde M, Larson TS, Textor SC, Griffin MD and Stegall MD: New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int. 67:2415–2421. 2005. View Article : Google Scholar : PubMed/NCBI
4	Revanur VK, Jardine AG, Kingsmore DB, Jaques BC, Hamilton DH and Jindal RM: Influence of diabetes mellitus on patient and graft survival in recipients of kidney transplantation. Clin Transplant. 15:89–94. 2001. View Article : Google Scholar : PubMed/NCBI
5	Kasiske BL, Snyder JJ, Gilbertson D and Matas AJ: Diabetes mellitus after kidney transplantation in the United States. Am J Transplant. 3:178–185. 2003. View Article : Google Scholar : PubMed/NCBI
6	Chowdhury TA: Post-transplant diabetes mellitus. Clin Med (Lond). 19:392–395. 2019. View Article : Google Scholar : PubMed/NCBI
7	Bloom RD and Crutchlow MF: New-onset diabetes mellitus in the kidney recipient: Diagnosis and management strategies. Clin J Am Soc Nephrol. 3 (Suppl 2):S38–S48. 2008. View Article : Google Scholar : PubMed/NCBI
8	Vincenti F, Friman S, Scheuermann E, Rostaing L, Jenssen T, Campistol JM, Uchida K, Pescovitz MD, Marchetti P, Tuncer M, et al: Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant. 7:1506–1514. 2007. View Article : Google Scholar : PubMed/NCBI
9	Chakkera HA, Kudva Y and Kaplan B: Calcineurin inhibitors: Pharmacologic mechanisms impacting both insulin resistance and insulin secretion leading to glucose dysregulation and diabetes mellitus. Clin Pharmacol Ther. 101:114–120. 2017. View Article : Google Scholar : PubMed/NCBI
10	van Hooff JP, Christiaans MH and van Duijnhoven EM: Tacrolimus and posttransplant diabetes mellitus in renal transplantation. Transplantation. 79:1465–1469. 2005. View Article : Google Scholar : PubMed/NCBI
11	Caillard S, Eprinchard L, Perrin P, Braun L, Heibel F, Moreau F, Kessler L and Moulin B: Incidence and risk factors of glucose metabolism disorders in kidney transplant recipients: Role of systematic screening by oral glucose tolerance test. Transplantation. 91:757–764. 2011. View Article : Google Scholar : PubMed/NCBI
12	Ishihara H, Asano T, Tsukuda K, Katagiri H, Inukai K, Anai M, Kikuchi M, Yazaki Y, Miyazaki JI and Oka Y: Pancreatic beta cell line MIN6 exhibits characteristics of glucose metabolism and glucose-stimulated insulin secretion similar to those of normal islets. Diabetologia. 36:1139–1145. 1993. View Article : Google Scholar : PubMed/NCBI
13	Huang X, Liu G, Guo J and Su Z: The PI3K/AKT pathway in obesity and type 2 diabetes. Int J Biol Sci. 14:1483–1496. 2018. View Article : Google Scholar : PubMed/NCBI
14	Engelman JA, Luo J and Cantley LC: The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 7:606–619. 2006. View Article : Google Scholar : PubMed/NCBI
15	Wullschleger S, Loewith R and Hall MN: TOR signaling in growth and metabolism. Cell. 124:471–484. 2006. View Article : Google Scholar : PubMed/NCBI
16	Redmon JB, Olson LK, Armstrong MB, Greene MJ and Robertson RP: Effects of tacrolimus (FK506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T15 cells. J Clin Invest. 98:2786–2793. 1996. View Article : Google Scholar : PubMed/NCBI
17	Johnson JD, Ao Z, Ao P, Li H, Dai LJ, He Z, Tee M, Potter KJ, Klimek AM, Meloche RM, et al: Different effects of FK506, rapamycin, and mycophenolate mofetil on glucose-stimulated insulin release and apoptosis in human islets. Cell Transplant. 18:833–845. 2009. View Article : Google Scholar : PubMed/NCBI
18	Sakata N, Egawa S, Sumi S and Unno M: Optimization of glucose level to determine the stimulation index of isolated rat islets. Pancreas. 36:417–423. 2008. View Article : Google Scholar : PubMed/NCBI
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
20	Prokai A, Fekete A, Pasti K, Rusai K, Banki NF, Reusz G and Szabo AJ: The importance of different immunosuppressive regimens in the development of posttransplant diabetes mellitus. Pediatr Diabetes. 13:81–91. 2012. View Article : Google Scholar : PubMed/NCBI
21	Rangel EB: Tacrolimus in pancreas transplant: A focus on toxicity, diabetogenic effect and drug-drug interactions. Expert Opin Drug Metab Toxicol. 10:1585–1605. 2014. View Article : Google Scholar : PubMed/NCBI
22	Rysz J, Franczyk B, Radek M, Ciałkowska-Rysz A and Gluba-Brzózka A: Diabetes and cardiovascular risk in renal transplant patients. Int J Mol Sci. 22:34222021. View Article : Google Scholar : PubMed/NCBI
23	Drachenberg CB, Klassen DK, Weir MR, Wiland A, Fink JC, Bartlett ST, Cangro CB, Blahut S and Papadimitriou JC: Islet cell damage associated with tacrolimus and cyclosporine: Morphological features in pancreas allograft biopsies and clinical correlation. Transplantation. 68:396–402. 1999. View Article : Google Scholar : PubMed/NCBI
24	Soleimanpour SA, Crutchlow MF, Ferrari AM, Raum JC, Groff DN, Rankin MM, Liu C, De León DD, Naji A, Kushner JA and Stoffers DA: Calcineurin signaling regulates human islet {beta}-cell survival. J Biol Chem. 285:40050–40059. 2010. View Article : Google Scholar : PubMed/NCBI
25	Speckmann T, Sabatini PV, Nian C, Smith RG and Lynn FC: Npas4 transcription factor expression is regulated by calcium signaling pathways and prevents tacrolimus-induced cytotoxicity in pancreatic beta cells. J Biol Chem. 291:2682–2695. 2016. View Article : Google Scholar : PubMed/NCBI
26	Sottero B, Gargiulo S, Russo I, Barale C, Poli G and Cavalot F: Postprandial dysmetabolism and oxidative stress in type 2 diabetes: Pathogenetic mechanisms and therapeutic strategies. Med Res Rev. 35:968–1031. 2015. View Article : Google Scholar : PubMed/NCBI
27	Rehman K and Akash MSH: Mechanism of generation of oxidative stress and pathophysiology of type 2 diabetes mellitus: How are they interlinked? J Cell Biochem. 118:3577–3585. 2017. View Article : Google Scholar : PubMed/NCBI
28	Aouacheri O, Saka S, Krim M, Messaadia A and Maidi I: The investigation of the oxidative stress-related parameters in type 2 diabetes mellitus. Can J Diabetes. 39:44–49. 2015. View Article : Google Scholar : PubMed/NCBI
29	Pérez Fernandez R, Martín Mateo MC, De Vega L, Bustamante Bustamante J, Herrero M and Bustamante Munguira E: Antioxidant enzyme determination and a study of lipid peroxidation in renal transplantation. Ren Fail. 24:353–359. 2002. View Article : Google Scholar
30	Tsikas D: Assessment of lipid peroxidation by measuring malondialdehyde (MDA) and relatives in biological samples, Analytical and biological challenges. Anal Biochem. 524:13–30. 2017. View Article : Google Scholar : PubMed/NCBI
31	Noberasco G, Odetti P, Boeri D, Maiello M and Adezati L: Malondialdehyde (MDA) level in diabetic subjects. Relationship with blood glucose and glycosylated hemoglobin. Biomed Pharmacother. 45:193–196. 1991. View Article : Google Scholar : PubMed/NCBI
32	Yepes-Calderón M, Sotomayor CG, Gomes-Neto AW, Gans ROB, Berger SP, Rimbach G, Esatbeyoglu T, Rodrigo R, Geleijnse JM, Navis GJ and Bakker SJL: Plasma malondialdehyde and risk of new-onset diabetes after transplantation in renal transplant recipients: A prospective cohort study. J Clin Med. 8:4532019. View Article : Google Scholar
33	Jin J, Jin L, Luo K, Lim SW, Chung BH and Yang CW: Effect of empagliflozin on tacrolimus-induced pancreas islet dysfunction and renal injury. Am J Transplant. 17:2601–2616. 2017. View Article : Google Scholar : PubMed/NCBI
34	Ho E, Karimi Galougahi K, Liu CC, Bhindi R and Figtree GA: Biological markers of oxidative stress: Applications to cardiovascular research and practice. Redox Biol. 1:483–491. 2013. View Article : Google Scholar : PubMed/NCBI
35	Vivanco I and Sawyers CL: The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2:489–501. 2002. View Article : Google Scholar : PubMed/NCBI
36	Engelman JA: Targeting PI3K signalling in cancer: Opportunities, challenges and limitations. Nat Rev Cancer. 9:550–562. 2009. View Article : Google Scholar : PubMed/NCBI
37	Whiteman EL, Cho H and Birnbaum MJ: Role of Akt/protein kinase B in metabolism. Trends Endocrinol Metab. 13:444–451. 2002. View Article : Google Scholar : PubMed/NCBI
38	Asano T, Fujishiro M, Kushiyama A, Nakatsu Y, Yoneda M, Kamata H and Sakoda H: Role of phosphatidylinositol 3-kinase activation on insulin action and its alteration in diabetic conditions. Biol Pharm Bull. 30:1610–1616. 2007. View Article : Google Scholar : PubMed/NCBI
39	Matheny RW Jr and Adamo ML: PI3K p110 alpha and p110 beta have differential effects on Akt activation and protection against oxidative stress-induced apoptosis in myoblasts. Cell Death Differ. 17:677–688. 2010. View Article : Google Scholar : PubMed/NCBI
40	Chen XW, Leto D, Xiong T, Yu G, Cheng A, Decker S and Saltiel AR: A Ral GAP complex links PI 3-kinase/Akt signaling to RalA activation in insulin action. Mol Biol Cell. 22:141–152. 2011. View Article : Google Scholar : PubMed/NCBI
41	Sudarsanam S and Johnson DE: Functional consequences of mTOR inhibition. Curr Opin Drug Discov Devel. 13:31–40. 2010.PubMed/NCBI
42	Rodriguez-Rodriguez AE, Donate-Correa J, Rovira J, Cuesto G, Luis-Ravelo D, Fernandes MX, Acevedo-Arozena A, Diekmann F, Acebes A, Torres A and Porrini E: Inhibition of the mTOR pathway: A new mechanism of β cell toxicity induced by tacrolimus. Am J Transplant. 19:3240–3249. 2019. View Article : Google Scholar : PubMed/NCBI
43	Slobodin B, Han R, Calderone V, Vrielink JAFO, Loayza-Puch F, Elkon R and Agami R: Transcription impacts the efficiency of mRNA Translation via Co-transcriptional N6-adenosine Methylation. Cell. 169:326–337.e12. 2017. View Article : Google Scholar : PubMed/NCBI
44	Juan Khong M and Ping Chong Ch: Prevention and management of new-onset diabetes mellitus in kidney transplantation. Neth J Med. 72:127–134. 2014.PubMed/NCBI